8-K: Brainstorm Cell Therapeutics Prices $4 Million Registered Direct Offering

Brainstorm Cell Therapeutics has announced a $4 million registered direct offering of common stock and warrants to a single institutional investor.

Summary

• Brainstorm Cell Therapeutics has entered into a securities purchase agreement for a registered direct offering.
• The offering includes 7,918,764 shares of common stock and pre-funded warrants to purchase up to 3,192,347 shares.
• Unregistered warrants to purchase up to 16,666,667 shares of common stock are also being issued in a concurrent private placement.
• The purchase price is $0.36 per share of common stock and accompanying warrant, or $0.35995 per pre-funded warrant and accompanying warrant.
• The offering is expected to yield gross proceeds of approximately $4.0 million before deducting fees and expenses.
• The warrants will be exercisable six months after issuance, expire five years after issuance, and have an exercise price of $0.3912 per share.
• Pre-funded warrants are immediately exercisable at $0.00005 per share and remain exercisable until fully exercised.
• The offering is expected to close on June 28, 2024, subject to customary closing conditions.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the dilutive nature of the offering and the reliance on a single institutional investor. While the capital raise is necessary for the company's operations, it comes at the cost of potential shareholder value dilution.

Positives

• The company is securing additional capital through this offering.
• The pre-funded warrants provide immediate access to potential future capital.
• The warrant amendment extends the life of existing warrants and reduces the exercise price, potentially increasing their value.

Negatives

• The offering will dilute existing shareholders.
• The exercise price of the new warrants is higher than the offering price of the common stock.
• The company is relying on a single institutional investor for this capital raise.

Risks

• The offering is subject to customary closing conditions, which may not be met.
• The company's stock price may be negatively impacted by the dilution from the offering.
• The company's ability to raise additional capital in the future may be affected by this offering.

Future Outlook

The company intends to file a registration statement for the resale of the warrant shares and use commercially reasonable efforts to have it declared effective by December 26, 2024.

Industry Context

This capital raise is typical for a biotech company in the clinical development stage, as they often require significant funding to advance their research and development programs. The use of a registered direct offering and private placement is a common approach to secure funding from institutional investors.

Comparison to Industry Standards

• The offering structure, combining a registered direct offering with a concurrent private placement of warrants, is a fairly standard approach for biotech companies seeking to raise capital.
• The pricing of the common stock and warrants is typical for a company with a market capitalization and share price similar to Brainstorm Cell Therapeutics.
• The use of a single institutional investor is not uncommon in these types of offerings, as it can streamline the process and reduce the complexity of the transaction.
• The warrant terms, including the exercise price and expiration date, are generally consistent with industry standards for similar financings.

Stakeholder Impact

• Existing shareholders will experience dilution of their ownership.
• The company will have additional capital to fund its operations.
• The institutional investor will gain a significant stake in the company.
• The company's employees may benefit from the company's increased financial stability.

Next Steps

• The company will close the offering on or about June 28, 2024.
• The company will file a prospectus supplement with the SEC.
• The company will file a registration statement for the resale of the warrant shares.
• The company will seek to list the new shares on the NASDAQ.

Key Dates

Keywords

registered direct offering, common stock, warrants, pre-funded warrants, capital raise, securities purchase agreement, placement agent, dilution, neurodegenerative diseases, stem cell therapeutics